Eurobio Scientific Shared Information from ESMO 2022 Industry Symposium
Eurobio Scientific released insights from an industry satellite symposium at ESMO 2022, focusing on the utility of the EndoPredict test in early breast cancer treatment decisions.
French biotechnology company Eurobio Scientific shared information in September 2022 regarding an industry satellite symposium held in conjunction with the European Society for Medical Oncology (ESMO) annual congress.
The symposium focused on the EndoPredict test, developed by Myriad Genetics. This genetic signature analysis aims to guide chemotherapy treatment decisions for specific patient groups, particularly premenopausal ER+/HER2- breast cancer patients.
Dr. Anastasia Constantinidou presented key new data from the ESMO 2022 congress. The findings illustrated how the EndoPredict test can aid clinicians in therapeutic decision-making and help avoid overtreatment for women diagnosed with early-stage breast cancer.
Eurobio Scientific specializes in molecular diagnostics for cancer detection and treatment. The company's offerings include various tests designed to support clinical decision-making and improve patient outcomes. The ESMO presentation highlighted the company's role in advancing cancer care research and providing access to diagnostic tools.